Taken together, the data indicate that BDMC plus icotinib caused synergistic growth inhibition in the TKI-resistant NSCLC cells depend on EGFR activity downregulation mediated by suppressing Sp1 expression and the interaction of Sp1 and HDCA1/HDCA2. Here, SP1 is linked to non-small cell lung carcinoma.